
Tokyo's Tuna King Opens His First-Ever U.S. Restaurant in Los Angeles
Restaurateur Kiyoshi Kimura, who is known as the 'Tuna King' in the famous Tsukiji Outer Market, opened the first Sushi Zanmai in 2001 in response to falling foot traffic. The restaurant quickly gained a dedicated following for its around-the-clock hours and affordable sushi. As Zanmai expanded, Kimura became a legend in his own right — in 2019, he paid a record 333.6 million yen (more than $2 million) for a single bluefin tuna at a New Year's auction. Purchasing the first fish of the year is considered an honor in Japan and attracts crowds to the restaurant.
On opening day, Kimura was on-site to cut into a 500-pound tuna in front of a crowd that amassed in the dining room. Donning a Zanmai-branded white coach's jacket and an apron, he used a katana-like sword to make the ceremonial first cuts. Kimura's team soon joined him to split the tuna open, exposing its ruby red flash; the head, which had been previously separated, sat in a rolling cart nearby. With a spoon, Kimura began to carefully carve out chunks of tuna, dropping them onto awaiting plates as servers distributed them to the diners in a flurry. The room quieted as the fish was covered, with guests sitting back down at their tables.
Kiyoshi Kimura at Sushi Zanmai. Rebecca Roland
500 pound tuna at Sushi Zanmai's opening day. Rebecca Roland
Except for the opening, Los Angeles diners will likely encounter a statue of a smiling Kimura with his outstretched arms. The interior resembles the Japanese locations, with a casual, minimalist design and an extensive sushi bar that runs the length of the room. A pergola-like wood structure sits above the dining room, with a handful of two and four-top tables below. Guests order off personal iPads on each table, which sends the ticket directly to the kitchen. The sushi, which is mainly served on black stones, comes out quickly, just minutes after placing an order.
The menu at Sushi Zanmai is straightforward, with crowd-pleasing hand rolls, cut rolls, nigiri, and more. Starters comprise dishes like edamame, shishito peppers, and spicy tuna crispy rice, topped with a thin slice of jalapeno. Other smaller, shareable dishes include agedashi tofu, sunomono cucumber, chawanmushi, karaage, and miso black cod.
Tuna passed around at Sushi Zanmai's opening. Rebecca Roland
As for sushi, Zanmai offers cut rolls filled with salmon, yellowtail, spicy tuna, natto, shrimp tempura, and more. Signatures include the Tsukiji with seared crab on a shrimp tempura roll, and the Hokkaido, with seared salmon on a California roll. Nigiri, which comes with one piece per order, is available with various cuts like toro, salmon belly, and whitefish; combination sets are priced between $8 for three pieces and $55 for the deluxe set. Zanmai offers four chirashi bowls, priced between $28 and $35, topped with toro, soy-marinated tuna, albacore, and more.
To complement the sushi, Zanmai also serves hot or cold udon and soba, alongside tempura and a handful of salads. Toban, dishes prepared in traditional Japanese ceramic cookware, come with a choice of salmon, tuna, oyster, tofu steak, vegetables, or mushrooms; each is between $13 and $22 and works as a shareable dish or dinner for one with the addition of some sides. Bento boxes, priced at $32, include three pieces of sushi and six pieces of sashimi, plus tempura, edamame, and a choice of proteins like grilled mackerel, chicken teriyaki, grilled salmon, and karaage.
After that first day, business at Sushi Zanmai settled back into a quiet lull, servers made a point to recommend the tuna, recounting the story of Kimura and his sword as if it were already a local legend. Even just days after its opening, one thing has already become clear: the tuna king is here to stay.
Sushi Zanmai is located at 3465 W. Sixth Street, Los Angeles, CA 90020, and is open seven days a week from 11:30 A.M. to 2:30 P.M. and 5:30 P.M. to 12 A.M.
Statue of Kiyoshi Kimura. Rebecca Roland
Sushi bar. Rebecca Roland
Dining room at Sushi Zanmai. Rebecca Roland
Salmon hand roll. Sushi Zanmai
Tsukiji roll. Sushi Zanmai
Toban. Sushi Zanmai
Chirashi bowl. Sushi Zanmai
Tuna nigiri. Sushi Zanmai
Nigiri. Sushi Zanmai
Sashimi. Sushi Zanmai
Eater LA
All your essential food and restaurant intel delivered to you Email (required)
Sign Up
By submitting your email, you agree to our Terms and Privacy Notice . This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Nicox's Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan
Press Release Nicox's Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan Exclusive Japanese partner Kowa has initiated a Phase 3 safety clinical trial of NCX 470 for the treatment of ocular hypertension in Japan Triggers a €2 million milestone payment to Nicox August 5, 2025 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that its exclusive Japanese partner, Kowa, has initiated a Phase 3 safety clinical trial of NCX 470 (also known as K-911) in Japan for the treatment of ocular hypertension, triggering a €2 million milestone payment to Nicox. Only one Phase 3 confirmatory clinical trial in Japanese patients, which will start shortly, plus this safety trial, is required for submission for marketing approval of NCX 470 in Japan. Kowa is responsible for financing and managing the trials under the February 2024 license agreement with Nicox.'Thanks to our continuing collaborative efforts after Kowa received approval to initiate this trial, we are very pleased to announce that the first patient has been enrolled. The Phase 3 trials in Japan are being managed and financed by Kowa, and only one confirmatory Phase 3 trial is expected to be needed to make a submission for marketing approval of NCX 470 in Japan.' said Doug Hubatsch, EVP Scientific Officer of Nicox. The trial announced today is a safety trial and is detailed here: JRCT Safety Trial NCX 470. The 500 patient confirmatory trial is expected to start shortly and is detailed here: JRCT Confirmatory Trial NCX NCX 470NCX 470, Nicox's lead clinical product candidate, is a novel NO-donating bimatoprost eye drop, currently in Phase 3 clinical development programs in the U.S., China and Japan for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Results of Mont Blanc, the first of the Phase 3 clinical trials, have been extensively published and are available on our website. All patients have completed the second Phase 3 clinical trial, Denali, and topline results are expected mid-August to mid-September 2025. Mont Blanc and Denali have been designed to fulfil the regulatory requirements for safety and efficacy Phase 3 trials to support NDA submissions in both the U.S. and in China. A separate Phase 3 clinical program is underway to support Japanese approval. NCX 470 is exclusively licensed to Ocumension Therapeutics in China, Korea and Southeast Asia and to Kowa in the rest of the world. About Nicox Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa elsewhere. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox's first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information Analyst coverage H.C. Wainwright & Co Yi Chen New York, views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@ Disclaimer The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking factors which are likely to have a material effect on Nicox's business are presented in section 3 of the 'Rapport Annuel 2024' which is available on Nicox's website ( this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail. Nicox Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 Attachment EN_NCX470KowaFPFVAugust2025_PR_FINAL
Yahoo
40 minutes ago
- Yahoo
Asian Market Value Picks: 3 Companies That May Be Trading Below Intrinsic Estimates
Amidst global economic uncertainties and fluctuating trade policies, Asian markets have shown resilience, with varying impacts on indices across the region. This environment presents opportunities for discerning investors to explore stocks that may be trading below their intrinsic value, particularly those with strong fundamentals and potential for growth despite external pressures. Top 10 Undervalued Stocks Based On Cash Flows In Asia Name Current Price Fair Value (Est) Discount (Est) Xi'an NovaStar Tech (SZSE:301589) CN¥155.51 CN¥309.46 49.7% SpiderPlus (TSE:4192) ¥506.00 ¥997.79 49.3% Ningbo Sanxing Medical ElectricLtd (SHSE:601567) CN¥22.88 CN¥45.72 50% Nanya Technology (TWSE:2408) NT$43.75 NT$87.13 49.8% Nan Ya Printed Circuit Board (TWSE:8046) NT$176.50 NT$350.51 49.6% Insource (TSE:6200) ¥926.00 ¥1843.53 49.8% H.U. Group Holdings (TSE:4544) ¥3254.00 ¥6446.96 49.5% Elan (TSE:6099) ¥850.00 ¥1696.06 49.9% cottaLTD (TSE:3359) ¥441.00 ¥871.25 49.4% Astroscale Holdings (TSE:186A) ¥676.00 ¥1333.68 49.3% Click here to see the full list of 274 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Let's take a closer look at a couple of our picks from the screened companies. Beijing HyperStrong Technology Overview: Beijing HyperStrong Technology Co., Ltd. designs, develops, integrates, and operates energy storage power stations across China, Europe, North America, and Australia with a market cap of CN¥16.64 billion. Operations: The company's revenue segments include the design, development, integration, and operation of energy storage power stations across its key markets in China, Europe, North America, and Australia. Estimated Discount To Fair Value: 37.2% Beijing HyperStrong Technology is trading at CN¥92.37, significantly below its estimated fair value of CN¥147.06, suggesting it may be undervalued based on cash flows. Its revenue and earnings are forecast to grow over 30% annually, outpacing the Chinese market's growth rates. However, its dividend yield of 1.19% is not well covered by free cash flows. Recent innovations like the HyperBlock M enhance its competitive edge in energy storage solutions through modularity and efficiency improvements. Upon reviewing our latest growth report, Beijing HyperStrong Technology's projected financial performance appears quite optimistic. Unlock comprehensive insights into our analysis of Beijing HyperStrong Technology stock in this financial health report. Shenzhen KSTAR Science and Technology Overview: Shenzhen KSTAR Science and Technology Co., Ltd. operates in the technology sector, focusing on power electronics and renewable energy solutions, with a market cap of CN¥13.86 billion. Operations: Unfortunately, the provided text does not contain specific revenue segment information for Shenzhen KSTAR Science and Technology Co., Ltd. Estimated Discount To Fair Value: 48.5% Shenzhen KSTAR Science and Technology is trading at CN¥23.8, well below its estimated fair value of CN¥46.24, indicating potential undervaluation based on cash flows. The company's revenue is projected to grow 22.3% annually, surpassing the Chinese market's average growth rate. Despite a forecasted earnings growth of 32.4%, profit margins have declined from last year, and the dividend track record remains unstable with recent reductions in payouts for 2024 dividends. The growth report we've compiled suggests that Shenzhen KSTAR Science and Technology's future prospects could be on the up. Click here to discover the nuances of Shenzhen KSTAR Science and Technology with our detailed financial health report. Qingdao Baheal Medical Overview: Qingdao Baheal Medical INC. is involved in the research, development, production, wholesale, and retail of pharmaceutical products across China, the United States, Hong Kong, and the United Kingdom with a market cap of CN¥11.77 billion. Operations: Qingdao Baheal Medical INC. generates revenue through its activities in the research, development, production, wholesale, and retail sectors of pharmaceutical products across several international markets including China, the United States, Hong Kong, and the United Kingdom. Estimated Discount To Fair Value: 18.5% Qingdao Baheal Medical, trading at CN¥22.39, is priced below its fair value estimate of CN¥27.46, reflecting potential undervaluation based on cash flows. Despite a volatile share price recently, earnings are projected to grow significantly at 20.05% annually over the next three years, although this lags behind the broader Chinese market's growth rate. The company affirmed a dividend payout for 2024, which may appeal to income-focused investors amid stable revenue growth projections of 13% per year. In light of our recent growth report, it seems possible that Qingdao Baheal Medical's financial performance will exceed current levels. Click here and access our complete balance sheet health report to understand the dynamics of Qingdao Baheal Medical. Turning Ideas Into Actions Unlock more gems! Our Undervalued Asian Stocks Based On Cash Flows screener has unearthed 271 more companies for you to here to unveil our expertly curated list of 274 Undervalued Asian Stocks Based On Cash Flows. Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance. Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world. Searching for a Fresh Perspective? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SHSE:688411 SZSE:002518 and SZSE:301015. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

an hour ago
Australia selects Japan's Mitsubishi Heavy Industries for $6.5B warship deal
WELLINGTON, New Zealand -- WELLINGTON, New Zealand (AP) — Australia said Tuesday it accepted a Japanese company's bid for a lucrative and hotly contested contract to build Australian warships, expected to be worth 10 billion Australian dollars ($6.5 billion). Mitsubishi Heavy Industries' Mogami-class frigate won the deal over rival Germany's MEKO A-200 from Thyssenkrupp Marine Systems. Japan's government lobbied heavily for the deal after missing out on Australia's submarines contract to a French company in 2016. 'This is clearly the biggest defense industry agreement that will ever have been struck between Japan and Australia,' Defense Minister Richard Marles told reporters when he announced the deal Tuesday. 'In fact, it's really one of the biggest defense exports that Japan has ever engaged in.' The fleet of 11 naval vessels will replace Australia's ageing fleet of ANZAC-class ships. Three of the frigates will be built in Japan, with the first scheduled to be operational Australia in 2030, and the remaining eight due for construction in Australia. Australian news outlets reported that the German company's bid had emphasized their vessel's cheaper price and their greater experience building ships abroad. But Pat Conroy, Australia's Minister for Defense Industry, said the Mogami-class frigate was a 'clear winner' when assessed by 'cost, capability and meeting our schedule of delivery.' The vessels have a range of up to 10,000 nautical miles (18,520 kilometers) and 32 vertical launch cells capable of launching long-range missiles. The frigates can operate with a crew of 90, compared to the 170 needed to operate the ANZAC-class ships. Mitsubishi's win was a boon for Japan's defense industry, which has not built naval vessels abroad before. Japan, whose only treaty ally is the United States, considers Australia a semi-ally and has increasingly sought to deepen bilateral military cooperation amid ongoing regional tensions in the disputed South China Sea. 'We welcome the decision by the Australian government as a major step to further elevate Japan's national security cooperation with Australia, which is our special strategic partner,' Japan's Defense Minister Gen Nakatani said Tuesday. Nakatani said co-developing the frigate will allow the two countries to train and operate with the same equipment and further improve operability and efficiency. Japan set up a joint taskforce of government and industry in an effort to win the bid. Australian officials said work on a binding commercial contract with Mitsubishi Heavy Industries and the government of Japan would now begin, with a finalized agreement expected in 2026. They did not say how much each ship would cost or confirm a total figure for the package, citing ongoing negotiations. But Conroy said the government had allowed AU$10 billion for the project over the next 10 years. It forms part of the AU$55 billion that Australia has budgeted for the navy's entire surface combatant fleet during the same period. —-